secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2026-09-01T20:13:12+00:00
Accession:  0001367644-26-000088
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions gets $24M BARDA contract modification for CYFENDUS anthrax vaccine
--------------------------------------------------------------------------------

- Contract modification valued at ~$24M from BARDA to supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness.
- Modification No. 21 to BARDA AV7909 Contract, effective Aug 18, 2026; announced Sept 1, 2026.
- Earlier in 2026, Emergent announced up to $21.5M delivery order for BioThrax to U.S. Department of War.
- CYFENDUS approved by FDA in July 2023 as two-dose anthrax vaccine for post-exposure prophylaxis in adults 18-65.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/0001367644-26-000088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764426000088/ebs-20260818.htm
  HTML page:      https://secwatch.observer/filing/0001367644-26-000088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer